Skip to main content

Advertisement

Table 2 Base case results representing an annual cohort from England (primary outcomes)

From: A model-based assessment of the cost–utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

Strategy 1(2) 2 3 4 5 6 7 8
Incremental costs vs Strategy 1(1) [£ Thousands]
Diagnosis 48.9 662.7 578.5 599.6 586.0 636.9 1061.6 1336.6
CRC prevention 396.7 735.9 726.9 822.1 817.1 817.1 928.8 1065.7
CRC treatment −249.3 −646.9 −646.2 −725.5 −725.2 −725.2 −814.0 −848.8
EC prevention 210.4 338.1 333.2 377.3 374.5 374.5 427.0 499.6
EC treatment −21.7 −60.6 −60.6 −68.0 −68.0 −68.0 −76.2 −78.7
Total 384.9 1029.2 931.8 1005.4 984.5 1035.3 1527.1 1974.5
Incremental QALYs vs Strategy 1(1)
Short-term 0 −4.3 −4.1 −4.8 −4.6 −4.6 −5.5 −8.5
Long-term 63.9 164.0 163.9 184.0 183.9 183.9 206.4 214.8
Total 63.9 159.7 159.8 179.2 179.3 179.3 200.9 206.3
Cost–utility
ICER vs Strategy 1(1) [cost per QALY gained] £6021 £6444 £5831 £5610 £5491 £5774 £7601 £9571
ICER [cost per QALY gained] ED D ED D £5491 D £25106 £82962
INHB at WTP £20000/QALY vs 1(1) [QALYs] 44.7 108.3 113.2 129.0 130.1 127.5 124.5 107.6
  1. Key: D, dominated; EC, endometrial cancer; ED, extended dominated; WTP, willingness-to-pay.